The Customs Logic
Customs agencies in every developed jurisdiction operate on a similar logic. Inbound parcels are subject to inspection. Inspection prioritization is determined by origin country, shipper history, declared contents, parcel weight and shape, x-ray characteristics, and intelligence-driven targeting on known-suspect categories. Research peptides are flagged in most major jurisdictions because peptide shipments have a distinctive signature: small, lightweight, often from China or Eastern Europe, often with a declared value or description that does not match the contents. Once a parcel is identified for inspection, the agency has authority under domestic medicines or drug law to detain, sample, and seize.
The vendor's choice of declared customs description matters more than most researchers realize. A parcel declared as "research chemical, value $25" is a different inspection-prioritization target than a parcel declared as "supplement powder, gift, value $5." Vendors who survive in this market generally use declaration patterns that minimize inspection triggers. Vendors who use accurate research-chemical declarations face higher seizure rates; vendors who use deliberately misleading declarations face higher seizure rates when detected and additionally expose the recipient to customs-fraud liability.
Seizure Rate Estimates We Have Observed
Across our own test orders and reader-submitted data, the rough seizure-rate patterns by origin/destination corridor:
| Origin | Destination | Approximate Seizure Rate | Notes |
|---|
| China | United States | 10-25% | Varies by port of entry, declaration accuracy, vendor sophistication |
| China | UK / EU | 30-50% | Higher inspection priority for medicine-category shipments |
| China | Australia | 50-75% | TGA + Border Force coordinated targeting |
| EU | United States | 5-15% | Intra-developed shipments inspected less aggressively |
| US domestic | US domestic | Approaching zero | Domestic shipments not routinely inspected |
| EU intra-EU | EU intra-EU | Low | Schengen free movement; intra-bloc inspection rare |
These ranges are estimates from limited samples and should not be treated as precise. The specific rate any individual researcher experiences will depend on order frequency, vendor declaration practices, port-of-entry routing, and seasonal variation in customs enforcement priorities.
The Seizure Notice and What To Do With It
When a U.S. parcel is seized, the recipient typically receives a Form 5310 ("Notice of Detention") or Form 5400 ("Notice of FDA Action") in the mail. The notice will identify the parcel, describe the basis for detention (usually "appears to be an unapproved new drug"), and provide options. The standard options are: (1) provide information satisfactory to the agency demonstrating the parcel is admissible, (2) request administrative destruction without contest, (3) abandon the parcel, or (4) request a formal hearing.
For research peptide shipments, options 1 and 4 are essentially never used by individual recipients. The reason is structural: contesting the seizure requires the recipient to engage in correspondence about the parcel's nature and intended use, which creates a documented record that the recipient sought human-use compounds. Option 2 or 3 is the standard recipient response. The parcel is destroyed; the recipient loses the cost of the order; no further consequence typically follows for personal-scale shipments.
Larger or repeated seizures can trigger additional scrutiny. We have heard from a small number of readers whose parcels triggered a follow-up letter requesting information about prior shipments. These are rare and seem to be associated with high-volume receivers who may have inadvertently registered as a "frequent receiver of suspect goods" in CBP's targeting systems.
Declaration Honesty: The Trade-Off
Some vendors offer a "declare as gift" or "declare as supplement" option at checkout. Customers should understand the trade-off explicitly. Accurate declaration as "research chemical, value $X" raises seizure probability but, in the event of seizure or scrutiny, makes the recipient less exposed to misdeclaration consequences. Misleading declaration as a different product lowers seizure probability but, if detected, exposes the recipient to customs-fraud allegations in addition to the underlying medicine-law issue. For personal-scale shipments, both pathways carry low documented enforcement risk to the individual recipient. The decision between them is a personal risk preference, not a clear-cut better-or-worse choice.
Domestic Vendor Logistics
Most U.S. researchers who have done the math eventually conclude that domestic vendors provide better total economics than international, even accounting for the higher per-unit price of domestic product. The reason: zero seizure rate, faster shipping, more responsive customer service, and the practical ability to pursue chargeback or refund if something goes wrong. The roughly 1.5-2x price premium for domestic-supplied research peptides represents, in effect, a logistical insurance premium against the international seizure risk.
That math changes for compounds where domestic supply is limited or for buyers in jurisdictions without a meaningful domestic research-supply market. For UK-based or Australian researchers, "domestic supply" is largely fictional, and the trade-off is between international seizure risk and clinic-mediated supply at substantially higher cost.
What Customs Cannot Do
It is worth being clear about what is not normally on the table. CBP cannot, under normal procedures: enter your residence, prosecute you criminally for receipt of a personal-scale research-peptide shipment, garnish your assets, or place you on a no-fly list. Customs interactions in the personal-receiver context end with parcel disposition and, occasionally, a follow-up letter requesting voluntary information about prior shipments. The criminal enforcement universe for unapproved drugs in the U.S. exists, but it is overwhelmingly oriented toward commercial distributors, not personal receivers. We have not been able to identify a U.S. criminal case against an individual personal receiver of research peptides in any of the published case law databases we have searched.
That does not make the activity safe, smart, or risk-free. It does mean that the catastrophic outcomes that some online discussions imply are not the documented norm. The documented norm for an unsophisticated individual receiver is: occasional package loss, occasional product quality issues, no further consequence.
Where To Go From Here
Reading any individual page on this site is a slice of the picture. The full investigation continues across the related desks. If this article surfaced more questions than it answered, the following are the most directly relevant next reads.
Editorial Standards
This report is updated periodically. Discrepancies between our reporting and reality are taken seriously — if you have observed something that contradicts what is published here, send it to the editorial desk with documentation and we will revise. Our reporting is constrained by what can be sourced, verified, or directly observed. Where evidence is weak we say so. Where it is absent we do not invent.
Wild West & Peptides receives no compensation from any vendor mentioned in this report, runs no affiliate program, and has no commercial relationship with the research-peptide industry it covers.